-$0.13 EPS Expected for Puma Biotechnology, Inc. (NASDAQ:PBYI) This Quarter

Wall Street brokerages expect Puma Biotechnology, Inc. (NASDAQ:PBYIGet Rating) to report earnings of ($0.13) per share for the current quarter, according to Zacks. Two analysts have made estimates for Puma Biotechnology’s earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.12). Puma Biotechnology reported earnings per share of $0.40 in the same quarter last year, which would suggest a negative year over year growth rate of 132.5%. The firm is expected to issue its next quarterly earnings results after the market closes on Monday, January 1st.

On average, analysts expect that Puma Biotechnology will report full year earnings of $0.15 per share for the current fiscal year, with EPS estimates ranging from $0.06 to $0.23. For the next financial year, analysts expect that the company will post earnings of $0.58 per share, with EPS estimates ranging from $0.35 to $0.81. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Puma Biotechnology.

Puma Biotechnology (NASDAQ:PBYIGet Rating) last posted its earnings results on Thursday, March 3rd. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.21. The firm had revenue of $55.40 million for the quarter, compared to analyst estimates of $47.17 million. Puma Biotechnology had a negative return on equity of 357.74% and a negative net margin of 11.49%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.38) earnings per share.

Several research analysts have weighed in on PBYI shares. Zacks Investment Research upgraded Puma Biotechnology from a “strong sell” rating to a “hold” rating and set a $2.25 target price on the stock in a report on Monday, February 14th. StockNews.com started coverage on Puma Biotechnology in a report on Thursday, March 31st. They issued a “hold” rating on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.45.

PBYI stock opened at $2.36 on Friday. The business’s 50-day moving average price is $2.76 and its two-hundred day moving average price is $3.20. The firm has a market cap of $97.54 million, a PE ratio of -3.28 and a beta of 1.02. Puma Biotechnology has a 1-year low of $2.06 and a 1-year high of $11.95.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. raised its holdings in Puma Biotechnology by 18.3% during the second quarter. Invesco Ltd. now owns 12,825 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 1,980 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in Puma Biotechnology by 64.4% during the fourth quarter. BNP Paribas Arbitrage SA now owns 11,354 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 4,447 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Puma Biotechnology by 13.2% during the fourth quarter. Principal Financial Group Inc. now owns 50,445 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 5,883 shares in the last quarter. Diversified Trust Co raised its holdings in Puma Biotechnology by 30.8% during the fourth quarter. Diversified Trust Co now owns 25,688 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 6,053 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in Puma Biotechnology by 2.9% during the second quarter. Wells Fargo & Company MN now owns 224,470 shares of the biopharmaceutical company’s stock worth $2,062,000 after buying an additional 6,314 shares during the last quarter. Institutional investors and hedge funds own 89.99% of the company’s stock.

Puma Biotechnology Company Profile (Get Rating)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.

See Also

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.